Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database

被引:36
作者
Hamann, J
Ruppert, A
Auby, P
Pugner, K
Kissling, W
机构
[1] Tech Univ Munich, Klin Psychiat & Psychotherapie Tech, Ctr Dis Management, D-81675 Munich, Germany
[2] BMS, Munich, Germany
[3] European Med Org, Pharmaceut Res Inst, BMS, Waterloo, Belgium
关键词
antipsychotics; comedication; prescriptions; psychotropic drugs;
D O I
10.1097/00004850-200307000-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Data of prescribing practices for antipsychotics are of great interest with respect to quality of care. Consequently, we analysed all prescriptions under the statutory health insurance redeemed at pharmacies in Southern Germany between July 1999 and December 2001. The database covers prescriptions for approximately 25 million people. Up to 6% of the population were prescribed an antipsychotic at least once during the study period. Most prescriptions were for conventional antipsychotics and written by non-specialists. Patients receiving second generation antipsychotics were more likely to receive continuous antipsychotic therapy. For a large proportion of patients, antipsychotic polypharmacy, as well as comedication for somatic illnesses, were observed. In particular, drugs for the treatment of cardiovascular and metabolic disorders were frequently co-prescribed. Physicians should consider patients' cardiovascular and metabolic risk profile when making treatment choices. The data suggest that the majority of antipsychotics are used for the treatment of disorders other than schizophrenia. It is important to raise awareness among non-specialists about the indications, efficacy and side-effects of the antipsychotics because these physicians account for the majority of antipsychotic prescriptions. Int Clin Psychopharmacol 18:237-242 (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:237 / 242
页数:6
相关论文
共 19 条
[1]  
BAHLO E, 2001, INNOVATIONEN THERAPI, P77
[2]   Recent trends in antipsychotlic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy [J].
Clark, RE ;
Bartels, SJ ;
Mellman, TA ;
Peacock, WJ .
SCHIZOPHRENIA BULLETIN, 2002, 28 (01) :75-84
[3]  
*DGPPN, 1998, BEH SCH
[4]   Antipsychotic medication adherence: Is there a difference between typical and atypical agents? [J].
Dolder, CR ;
Lacro, JP ;
Dunn, LB ;
Jeste, DV .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01) :103-108
[5]   Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study [J].
Kasper, S ;
Rosillon, D ;
Duchesne, I .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (04) :179-187
[6]   Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials [J].
Leucht, S ;
Pitschel-Walz, G ;
Abraham, D ;
Kissling, W .
SCHIZOPHRENIA RESEARCH, 1999, 35 (01) :51-68
[7]   Epidemiology of prescriptions for neuroleptic drugs: Tranquilizers rather than antipsychotics [J].
Linden, M ;
Thiels, C .
PHARMACOPSYCHIATRY, 2001, 34 (04) :150-154
[8]   Good tolerability equals good results: the patient's perspective [J].
Naber, D ;
Karow, A .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 :391-396
[9]   Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia [J].
Sernyak, MJ ;
Leslie, DL ;
Alarcon, RD ;
Losonczy, MF ;
Rosenheck, R .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (04) :561-566
[10]  
*STAT BUND, 2002, STAT JB 2002 BUND RE